Edward Bilotti, MD
Psychiatry · South Portland, MENPI 1740344902
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,390 of the $87,619 with a category attached, or 74.6%. Johnson & Johnson accounts for 95.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $29,746 and has fallen 54.6% since, to $13,492 in 2025. Among psychiatry clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $197.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$84K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$542
- Lundbeck LLC$506
- Sunovion Pharmaceuticals Inc.$314
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$65,39075%
- Travel & lodging$14,17516%
- Food & beverage$8,0079%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 187 | $83,616 |
| Otsuka America Pharmaceutical, Inc. | 88 | $1,027 |
| AbbVie | 34 | $542 |
| Lundbeck LLC | 22 | $506 |
| Sunovion Pharmaceuticals Inc. | 24 | $314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $202 |
| Alkermes, Inc. | 11 | $195 |
| Indivior Inc. | 9 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $161 |
| Braeburn Inc. | 6 | $158 |
| Neurocrine Biosciences, Inc. | 17 | $140 |
| Teva Pharmaceuticals USA, Inc. | 6 | $133 |
| Axsome Therapeutics, Inc. | 7 | $125 |
| Corium, LLC | 7 | $98 |
| Vanda Pharmaceuticals Inc. | 4 | $94 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Livanova USA, Inc. | 1 | $42 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$80,686
How this compares
$87,619 in reported general payments places this provider in the 95th percentile of 167 psychiatry providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 473 | $553,745 |
| RexultiBrexpiprazole | 12 | $27,350 |
| TrintellixVortioxetine Hydrobromide | 25 | $20,767 |
| Duloxetine Hcl | 69 | $4,358 |
| Vilazodone Hcl | 28 | $4,175 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $3,571 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,852 |
| Clozapine | 26 | $1,304 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $1,234 |
| Bupropion XlBupropion Hcl | 63 | $1,035 |
| Aripiprazole | 35 | $973 |
| Clonazepam | 118 | $837 |
| Oxcarbazepine | 14 | $817 |
| Methylphenidate Hcl | 31 | $796 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $83,616 | $553,745473 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,027 | $27,35012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $161 | $20,76725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 167 psychiatry providers in Maine.
Other psychiatry in South Portland
- Ryan SmithEastport$92K
- Ira ScottBangor$27K
- Charmaine PatelBangor$17K
- Glenn CurrierPortland$8K
- Elliot GruenLewiston$7K
- David JonesArundel$5K
- Christine WhitePrinceton$2K
- Sally WeissBangor$2K
- Kenneth WhiteVinalhaven$2K
- Michael PatnaudeWestbrook$979
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.